The company's 3DKUBE technology platform incorporates perfusion flow, various scaffold materials, in situ imaging, and segregated cell co-culture to model complex human biology. Their single-use disposable assays leverage these features to predict drug toxicity and efficacy, aiding in the evaluation of treatments before human clinical trials. KIYATEC's advanced 3D cell culture technology helps medical practitioners identify effective treatments for cancer and tumor patients by analyzing cell-material interactions and predicting drug response.